Published in Allergy Asthma Immunol Res on July 01, 2016
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) (Aspirin) | NCT01597375
Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol (2016) 0.75
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol (2007) 15.45
Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 8.36
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med (2009) 5.90
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med (2007) 3.83
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med (2014) 3.50
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol (2012) 3.23
Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest (1998) 2.13
Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood (2012) 2.08
Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J (2000) 2.00
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med (2002) 1.90
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med (2014) 1.82
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol (2007) 1.77
Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med (2009) 1.71
Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis (1991) 1.59
Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract (2015) 1.52
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol (2011) 1.42
Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med (1996) 1.31
Evidence for distinct histologic profile of nasal polyps with and without eosinophilia. Laryngoscope (2011) 1.17
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther (2003) 1.15
The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol (2002) 1.14
Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A (2013) 1.12
Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2003) 1.12
Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol (1996) 1.10
Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res (2014) 1.10
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol (2014) 1.09
A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol (2003) 1.08
Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med (1994) 1.05
Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol (2014) 1.03
Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2014) 1.02
Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy (2005) 1.01
Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2006) 1.00
An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol (2007) 1.00
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. Allergol Int (2008) 0.98
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy (2008) 0.98
Aspirin sensitivity: implications for patients with coronary artery disease. JAMA (2004) 0.97
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf (2007) 0.93
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol (1984) 0.91
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. J Asthma (2007) 0.90
Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol (2013) 0.88
Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol (2005) 0.87
Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol (2003) 0.87
Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol (2014) 0.85
Medical and surgical considerations in patients with Samter's triad. Am J Rhinol (2006) 0.84
Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy (2014) 0.81
Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity. Allergy Asthma Immunol Res (2013) 0.79
Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice? Allergy Asthma Immunol Res (2015) 0.79
Cardiovascular prophylaxis and aspirin "allergy". Immunol Allergy Clin North Am (2012) 0.78
Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract (2015) 0.78
Aspirin exacerbated respiratory disease: the search for a biomarker. Ann Allergy Asthma Immunol (2014) 0.78
Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol (2010) 0.78
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. Otolaryngol Head Neck Surg (2014) 0.77
Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. Ann Allergy (1986) 0.76
Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity. J Korean Med Sci (1991) 0.76
Control of salicylate intolerance with fish oils. Br J Dermatol (2008) 0.76
Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J (2004) 0.76